Eichenfield LF, Yosipovitch G, Kalabis M, et al. - In this pooled post hoc analysis of two phase 3 trials, researchers sought to evaluate improvement and time to improvement in Investigator's Static Global Assessment (ISGA) and Severity of Pruritus Scale (SPS) outcomes in pediatric patients with mild‐to‐moderate AD. Individuals aged ≥ 2 years were randomly allocated 2:1 to obtain twice‐daily crisaborole or vehicle for 28 days. Patients aged 2 to 17 years were pooled for this analysis. At first postbaseline evaluation (day 8), significantly higher proportions of crisaborole‐ than vehicle‐treated patients achieved ISGA success, ISGA clear/almost clear, ≥1‐grade ISGA improvement, SPS success, or ≥1‐grade improvement in SPS independent of baseline ISGA. In pediatric patients with mild‐to‐moderate baseline AD, improvement in ISGA and SPS outcomes were noted with crisaborole.